Joshua E. Allen, Ph.D.
Affiliations: | 2012 | Biochemistry and Molecular Biophysics | University of Pennsylvania, Philadelphia, PA, United States |
Area:
Oncology, PharmacyGoogle:
"Joshua Allen"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Wafik S. El-Deiry | grad student | 2012 | Penn | |
| (Efficacy and mechanistic evaluation of TIC10, a novel antitumor agent.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Paraghamian SE, Qiu J, Hawkins GM, et al. (2023) A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer. Cancer Biology & Therapy. 24: 2202104 |
| Fan Y, Wang J, Fang Z, et al. (2022) Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer. Frontiers in Oncology. 12: 789450 |
| Tucker K, Yin Y, Staley SA, et al. (2022) ONC206 has anti-tumorigenic effects in human ovarian cancer cells and in a transgenic mouse model of high-grade serous ovarian cancer. American Journal of Cancer Research. 12: 521-536 |
| Anderson PM, Trucco MM, Tarapore RS, et al. (2022) Phase 2 Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Staley A, Tucker K, Yin Y, et al. (2021) Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer. American Journal of Cancer Research. 11: 5374-5387 |
| Mosquera MJ, Kim S, Bareja R, et al. (2021) Extracellular Matrix in Synthetic Hydrogel-based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 inhibitors. Advanced Materials (Deerfield Beach, Fla.). e2100096 |
| Allen JE, Kline CLB, Prabhu VV, et al. (2021) Correction: Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 12: 2231 |
| He L, Bhat K, Ioannidis A, et al. (2021) Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology |
| Pierce SR, Fang Z, Yin Y, et al. (2021) Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer. Journal of Experimental & Clinical Cancer Research : Cr. 40: 61 |
| Bagheri-Yarmand R, Dadu R, Ye L, et al. (2021) ONC201 shows anti-cancer activity against medullary thyroid cancer via transcriptional inhibition of RET, VEGFR2, and IGFBP2. Molecular Cancer Therapeutics |